勃起不全の市場規模、シェア、成長分析：治療タイプ別、エンドユーザー別、地域別 - 産業予測 2025～2032年

勃起不全の世界市場規模は2023年に25億米ドルと評価され、2024年の27億2,000万米ドルから2032年には53億4,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは8.8％で成長する見通しです。

勃起不全（ED）は、満足のいく勃起が得られない、または維持できない状態であり、最も一般的な男性の性の健康問題であり、身体的および精神的な幸福に大きな影響を与えます。この症状は心理的および生理的要因から生じ、後者には高血圧、肥満、糖尿病、喫煙などが含まれます。EDの有病率が上昇するにつれ、ヘルスケアプロバイダーや患者の意識の高まりによって、治療オプションの市場は拡大すると予想されます。しかし、陰茎インプラントに関連する高額な費用が、効果的な解決策を求める多くの人々にとって依然として大きな障壁となっているため、市場の成長は妨げられる可能性があります。全体として、ED治療市場は成長の態勢にあるが、価格設定が依然として重要な課題となっています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次データと一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析

勃起不全市場規模：治療タイプ別& CAGR（2025-2032）

• 市場概要
• 薬物
• シルデナフィル
• タダラフィル
• バルデナフィル
• アバナフィル
• その他
• 陰茎インプラント
• ペニスポンプ
• その他

勃起不全市場規模：エンドユーザー別& CAGR（2025-2032）

• 市場概要
• 病院・クリニック
• 外来手術センター
• 薬局
• その他

勃起不全市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 会社概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• Pfizer（US）
• Eli Lilly and Company（US）
• Bayer AG（Germany）
• Takeda Pharmaceutical Company（Japan）
• Mylan（US）（Now Viatris）
• Viatris（US）
• Teva Pharmaceutical Industries（Israel）
• Sun Pharmaceutical Industries（India）
• Cipla（India）
• Aurobindo Pharma（India）
• Lupin Limited（India）
• Dr. Reddy's Laboratories（India）
• Sandoz（Switzerland）
• Novartis（Switzerland）
• Abbott Laboratories（US）
• Sanofi（France）
• GlaxoSmithKline（GSK）（UK）
• Johnson & Johnson（US）
• Boston Scientific（US）
• Coloplast（Denmark）

結論と推奨事項

Global Erectile Dysfunction Market size was valued at USD 2.5 billion in 2023 and is poised to grow from USD 2.72 billion in 2024 to USD 5.34 billion by 2032, growing at a CAGR of 8.8% during the forecast period (2025-2032).

Erectile dysfunction (ED), the inability to achieve or maintain a satisfactory erection, is the most common male sexual health issue and significantly impacts both physical and mental well-being. The condition arises from psychological and physiological factors, with the latter including high blood pressure, obesity, diabetes, and smoking. As the prevalence of ED rises, the market for treatment options is expected to expand, driven by increasing awareness among healthcare providers and patients. However, market growth may be hindered by the high costs associated with penile implants, which remain a significant barrier for many looking for effective solutions. Overall, the ED treatment market is poised for growth, but pricing remains a critical challenge.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Erectile Dysfunction market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Erectile Dysfunction Market Segments Analysis

Global Erectile Dysfunction Market is segmented by Treatment Type, End User and region. Based on Treatment Type, the market is segmented into Drugs, Sildenafil, Tadalafil, Vardenafil, Avanafil, Others, Penile Implants, Penis Pumps and Others. Based on End User, the market is segmented into Hospitals & Clinics, Ambulatory Surgery Centers, Pharmacies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Erectile Dysfunction Market

The Global Erectile Dysfunction market is significantly influenced by the increasing prevalence of diabetes, obesity, and cardiovascular diseases, all of which are linked to unhealthy lifestyle choices. As people age, these conditions contribute to erectile dysfunction (ED), with a particularly concerning trend among younger individuals in emerging countries where stressful lifestyles have led to a rise in fast food consumption, as well as drinking and smoking habits. These factors are undermining overall health and fitness, thereby heightening the risk of developing ED. Moreover, with the senior population on the rise, the number of individuals suffering from ED is expected to increase, further propelling the demand for ED medications globally throughout the forecast period.

Restraints in the Global Erectile Dysfunction Market

The global erectile dysfunction market faces significant restraints, particularly in low- and middle-income countries where sales represent a smaller fraction compared to developed and emerging economies. This limitation stems from several factors, including a general lack of awareness regarding available treatments, restricted purchasing power among potential consumers, and resistance to integrating these medications into daily routines. Additionally, the market's growth is hindered by the adverse side effects associated with erectile dysfunction drugs, such as headaches, nausea, flushing, nasal congestion, visual disturbances, dizziness, diarrhea, and skin rashes, all of which discourage potential users from pursuing treatment options.

Market Trends of the Global Erectile Dysfunction Market

The global erectile dysfunction market is experiencing notable growth, driven primarily by the enduring popularity of sildenafil, commonly known as Viagra. As a cornerstone treatment, sildenafil has demonstrated significant efficacy, with approximately two-thirds of users reporting improved erections, reinforcing its status as the first-line therapy for erectile dysfunction. The market's expansion is further supported by increasing awareness of sexual health, a growing aging population, and the rising incidence of conditions like diabetes and hypertension that contribute to erectile dysfunction. As a result, the erectile dysfunction market is poised for robust growth throughout the projection period, fueled by advancements in treatment options and a rising demand for effective therapies.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Erectile Dysfunction Market Size by Treatment Type & CAGR (2025-2032)

• Market Overview
• Drugs
• Sildenafil
• Tadalafil
• Vardenafil
• Avanafil
• Others
• Penile Implants
• Penis Pumps
• Others

Global Erectile Dysfunction Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals & Clinics
• Ambulatory Surgery Centers
• Pharmacies
• Others

Global Erectile Dysfunction Market Size & CAGR (2025-2032)

• North America (Treatment Type, End User)
  • US
  • Canada
• Europe (Treatment Type, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment Type, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment Type, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment Type, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Pfizer (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan (US) (Now Viatris)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline (GSK) (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boston Scientific (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Coloplast (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations